Journal Articles- Refereed

Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen HJM, IJzerman MJ. Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population. Value Health. 2018 Nov;21(11):1269–77.

Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, IJzerman MJ et al. Matching the model with the evidence_ comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiol. Elsevier; 2018 Oct 12;57:60–7.

Heuvelmans MA, Vonder M, Rook M, Groen HJM, de Bock GH, Xie X, et al. Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations. J Thorac Imaging. 2018 Dec 13;:1.

de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, et al. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget. 2018 Nov 2;9(86):35705–16.

Berghuis AMS, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ. Evidence on the cost of breast cancer drugs is required for rational decision making. Ecancermedicalscience. 2018;12:825.

IJzerman MJ, Berghuis AMS, de Bono JS, Terstappen LWMM. Health economic impact of liquid biopsies in cancer management. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug 7;28(1):1–7.

Witteveen A, Nane GF, Vliegen IMH, Siesling S, IJzerman MJ. Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. Medical Decision Making. 2018 Oct; 38(7):822-833

Witteveen A, Siesling S, Otten JWM, Vliegen IMH, Timmer JB, IJzerman MJ. Risk-based breast cancer follow-up stratified by age. Cancer Med. 2018 Oct; 7(10):5291-5298